Evidence map›Paper›PMID 38333726›Full record

ArticleFrontiers in endocrinology2023

The first compound heterozygous mutations in SLC12A3 and PDX1 genes: a unique presentation of Gitelman syndrome with distinct insulin resistance and familial diabetes insights.

Yaqi Yin, Liqin Li, Songyan Yu, Yu Xin, Lili Zhu, Xiao Hu, Kang Chen, Weijun Gu, Yiming Mu, Li Zang and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yaqi Yin *Department of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Liqin Li *Department of Endocrinology, Baoding No. 1 Central Hospital, Baoding, China.
Songyan Yu *Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yu XinSchool of Medicine, Nankai University, Tianjin, China.
Lili ZhuDepartment of Endocrinology and Cardiology, TaiYuan No.8 People Hospital, Taiyuan, China.
Xiao HuDepartment of Internal Medicine, The 63790th Hospital of Chinese People's Liberation Army, Xichang, China.
Kang ChenDepartment of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Weijun GuDepartment of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Yiming MuDepartment of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Li ZangDepartment of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Zhaohui LyuDepartment of Endocrinology, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Chinese People's Liberation Army · CNBaoding People's Hospital · CNBeijing Tian Tan Hospital · CNFourth People's Hospital of Taiyuan · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gitelman Syndrome (GS) patients frequently exhibit disrupted glucose metabolism, attributed to hypokalemia, hypomagnesemia and heightened aldosterone. This study delved into the genetic underpinnings linked to insulin resistance and diabetes in a GS patient, contextualized within his family history. Methods: The hydrochlorothiazide and furosemide loading test were performed to ascertain the presence of GS. Oral glucose tolerance test (OGTT) evaluated glucose metabolism and insulin sensitivity. Whole-exome sequencing, validated by Sanger sequencing, was employed to confirm gene mutations, which were then tracked among the patient's relatives. Results: Symptoms and laboratory examination confirmed the clinical diagnosis of GS. Comprehensive whole-exome sequencing, augmented by Sanger sequencing validation, revealed a compound heterozygous mutation within the SLC12A3 gene (c.1108G>C in exon 9, c.676G>A in exon 5 and c.2398G>A in exon 20) in the patient. The OGTT affirmed diabetes and heightened insulin resistance, distinct from previous patients with GS we evaluated. Further genetic analysis identified a missense heterozygous mutation (c.97C>G in exon 1) within the PDX1 gene, inherited from the patient's diabetic mother without GS. Furthermore, the patient's brother, with impaired glucose tolerance but regular potassium levels, also bore this mutation, hinting at additional impacts of the PDX1 gene mutation on glucose metabolism regulation beyond the known impacts of GS. Conclusion: This study unveils unprecedented compound heterozygous mutations in the SLC12A3 and PDX1 genes in a GS patient. These findings illuminate the potential complex genetic factors influencing glucose metabolism disruptions in GS. Take-home message: This research uncovers a novel combination of SLC12A3 and PDX1 gene mutations in a Gitelman Syndrome patient, revealing intricate genetic factors that potentially disrupt glucose metabolism and shedding light on familial diabetes links.

Indexed as

Diabetes MellitusGitelman SyndromeInsulin ResistanceGlucoseHumansMaleMutationSolute Carrier Family 12, Member 3GlucoseSLC12A3 protein, humanSolute Carrier Family 12, Member 3Gitelman syndromeinsulin resistanceMODY4PDX1SLC12A3

Identifiers

PMID38333726
PMCPMC10850558
OpenAlexW4391227902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.